Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MGI Pharma has published data on its treatment for oral mucositis, a side effect of cancer therapies, suggesting that the drug Saforis reduced the incidence and severity of the disease in a phase III trial.
Subscribe to our email newsletter
Saforis is an investigational therapy for the treatment and prevention of oral mucositis in patients receiving mucotoxic cancer therapy. The phase III trial of Saforis was conducted in patients with breast cancer who were receiving anthracycline-based chemotherapy regimens.
The primary endpoint of this trial, defined as a reduction in incidence and severity of oral mucositis, was met. Data from this study indicate that the incidence of oral mucositis was 38.7% in Saforis-treated patients compared to 49.7% in patients who received placebo. Overall, the data indicated that the safety profile of Saforis was comparable with that of placebo.
However, the FDA has requested an additional phase III trial of Saforis before it will approve the drug. MGI Pharma said it is currently evaluating options to maximize the value of Saforis.